HS Research Update (2026-06-08): What's New on PubMed?

Publication Overview

This update includes 8 PubMed publications with an abstract from the monitoring period 2026-05-31 to 2026-06-08. The most common focus areas are comorbiditiesComorbidity: An additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression.ComorbidityAn additional condition existing alongside the primary disease. Acne Inversa is frequently associated with comorbidities including metabolic syndrome, inflammatory bowel disease, spondyloarthritis, and depression.Read more in the glossary, biologicsBiologic: A class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient.BiologicA class of medications derived from living cells that target specific components of the inflammatory process. For Acne Inversa, biologics such as adalimumab and secukinumab are used when other treatments are insufficient.Read more in the glossary, surgery, wound care, quality of life.

• Comparison to the previous update: not automatically assessed.
• No high-ranking guidelines/NEJM/Lancet hits with an abstract were found in this window.
• This selection is a research overview, not a guideline and not medical advice.

Top Highlights

The most important signals in this round are not found in a single treatment recommendation, but in the questions researchers are currently examining more closely: wound healing after procedures, new anti-inflammatory approaches, quality of care, and comorbidities.

• Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.: The abstract describes a systematic review. The main content is: Dietary factors have been suggested to influence inflammatory skin diseases; however, their role in the pathogenesis and clinical course of hidradenitis suppurativa (HS) remains insufficiently understood. Increasing e… What’s new or notable here is that HS is being examined from the perspective of surgery, wound care, comorbidities. The most important limitation: the strength of the evidence depends on how good and how comparable the included studies are; abstracts also don’t reveal every methodological weakness. (PMID 42233037)
• Joint pain and hidradenitis suppurativa: a retrospective cohort study.: The abstract describes a retrospective cohort study. The main content is: Joint pain was reported by 37% of patients with hidradenitis suppurativa (HS) at our single-centre HS clinic. However, only one-quarter of those reporting joint pain had a diagnosis of arthritis. What’s new or notable here is that HS is being examined from the perspective of pain, comorbidities. A separate article explains how possible joint involvement in HS can be interpreted. The most important limitation: as an observational analysis, this work can describe associations but cannot reliably prove cause-and-effect relationships. (PMID 42222703)
• A survey of UK-based dermatologists and Outpatient Parenteral Antimicrobial Therapy centres to evaluate the use of intravenous antibiotics as a treatment for hidradenitis suppurativa.: The abstract describes a survey-based analysis. The main content is: Case series have indicated that intravenous antibiotics may be effective in severe hidradenitis suppurativa (HS) treatment. This treatment approach is excluded from the British Association of Dermatologists UK HS trea… What’s new or notable here is that HS is being examined from the perspective of surgery, biologics. The most important limitation: surveys show current practice patterns and opinions, but not automatically which approach works best for patients. (PMID 42222698)
• IL-17 therapy and side-effect management: This publication addresses how mucosal and skin candidiasis under bimekizumabBimekizumab: A monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®.BimekizumabA monoclonal antibody blocking both IL-17A and IL-17F. Approved by the FDA on 20 November 2024 as the first IL-17A and IL-17F inhibitor for adults with moderate-to-severe HS; approved by the EMA in April 2024. Brand name: Bimzelx®.Read more in the glossary in HS could be prevented or treated early. What’s new here is less a proof of efficacy than the practical question of how treatment adherence and tolerability can be improved in everyday life. (PMID 42247110)
• Suicidal ideation in patients with skin conditions: A multicentre European study.: The abstract describes a multicentre study. The main content is: Suicidal ideation is a significant, often overlooked, concern in dermatologyDermatology: The medical specialty concerned with diagnosing and treating skin conditions. Acne Inversa is often managed by dermatologists, although surgery and other specialties may also be involved.DermatologyThe medical specialty concerned with diagnosing and treating skin conditions. Acne Inversa is often managed by dermatologists, although surgery and other specialties may also be involved.Read more in the glossary. Individuals with skin diseases frequently experience psychological distress, including depression, anxiety, stigmaStigma: The social devaluation patients experience because of visible or smellable Acne Inversa. Documented across cultures. A predictor of depression, social withdrawal, and employment difficulty — and one of the reasons patient education and visibility campaigns matter.StigmaThe social devaluation patients experience because of visible or smellable Acne Inversa. Documented across cultures. A predictor of depression, social withdrawal, and employment difficulty — and one of the reasons patient education and visibility campaigns matter.Read more in the glossary and dissatisfaction with… What’s new or notable here is that HS is being examined from the perspective of quality of life, comorbidities. The most important limitation: the abstract alone provides only limited insight into study design, patient selection, and follow-up time. (PMID 42246602)

Featured Publication

The featured work is Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review. from Frontiers in Immunology (PMID 42233037). The abstract is mainly about: Dietary factors have been suggested to influence inflammatory skin diseases; however, their role in the pathogenesis and clinical course of hidradenitis suppurativa (HS) remains insufficiently understood. Increasing e…

Why it stands out: The publication fits the focus themes surgery, wound care, comorbidities and shows which questions are currently being examined more closely in HS. It is relevant to readers mainly because it provides a concrete example of how research addresses an everyday topic or a possible mechanism. Metabolism-related aspects are also explored in more detail in the article on metabolic syndrome in Acne Inversa. The most important limitation remains: the strength of the evidence depends on how good and how comparable the included studies are; abstracts also don’t reveal every methodological weakness.

What This Could Mean for You (patient-friendly, without recommendations)

If you live with HS, research updates can help you make sense of terms and trends — for example, which measures (pain, quality of life) are used in studies or which comorbidities are being considered more often.

It’s important to note: even if individual studies sound exciting, they usually don’t yet say anything about what is right for you personally. Use new findings as a conversation starter (e.g. “What goals are realistic for me?” or “Which comorbidities should I keep an eye on?”) — not as instructions for action. Older posts such as the HS Research Update from June 1, 2026 offer further context.

What We Don’t Know / Limitations

• This update only includes PubMed entries with an abstract (without an abstract, a reliable summary is hardly possible).
• Studies vary greatly (design, population, measurement methods).
• This update provides no treatment recommendations and does not assess individual risks.

Important: Decisions Belong in the Doctor’s Office

This article is an editorial overview and has not been medically reviewed. If anything in this overview unsettles or interests you, use it as a conversation starter for your next appointment. Medications, surgeries, and diagnostics should always be discussed together with qualified medical professionals.

FAQ

Why does this only cover a few new publications?

This format filters strictly: only new PubMed entries within the monitoring window that have an abstract and have not already been covered in previous posts are included.

Does a new study mean my treatment should change?

No. Individual publications can be interesting, but they usually aren’t enough to draw conclusions for a specific person.

Why is so much emphasis placed on limitations and uncertainties?

Because abstracts only show part of the overall picture. Study design, patient population, endpoints, and follow-up time all need to be considered before interpreting results.

Sources & Original Studies

For each point, you’ll find the original source below (PubMed link, and DOI/PMCID where available).